One researcher in our network shifted from morning to pre-dinner dosing and saw mean satiety duration extend from 3.2 hours to 5.8 hours
So I wrote a little thing for @MolMetab sciencedirect.com/science/articl As we now appreciate, GLP-1 can target multiple brain regions and neuronal populations to reduce food intake, and the clinical results are increasingly impressive #obesity The ongoing SELECT trial will be pivotal for the field sciencedirect.com/science/articl From very modest weight loss with exenatide twice daily, the GLP-1 field has learned, by titration, dose escalation, higher Cmax, and better molecules, to achieve clinically meaningful #weightloss #T2D #obesity More progress to come #obesity described here sciencedirect.com/science/articl Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance Join the conversation
It's a recognition that the research community is actively exploring these synergistic pathways, and we aim to provide the highest-purity components for that advanced research
GDNF growth factors BBB blood- brain barrier permeability the invention provides small molecule mimetics (mimic) of the growth factor "hepatocyte growth factor (HGF) that are orally active, display profound growth factor activity, and are inexpensive to synthesize
